In the following video, Motley Fool health-care analyst David Williamson discusses Dendreon's strong quarterly results that included top-line growth. Dendreon announced preliminary results in early January, so many of the numbers weren't big news, but David takes investors through key takeaways from the conference call, including progress on Dendreon's restructuring, its surprising forecast for the current quarter, and why management thinks the future is bright.
Resurgence, or dead cat bounce?
Shares of Dendreon have surged in recent months, with the stock gaining new life from the depths of late 2012. Has the company really solved its underlying problems, or are investors setting themselves up for more disappointment? Our new premium research report on Dendreon answers these questions, and many more, while also outlining just how Dendreon intends to regain its former glory. Claim your copy, and a year of free analyst updates, by clicking here now.
The article Dendreon's Big Quarter: Key Takeaways originally appeared on Fool.com.
David Williamson has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson and owns shares of Dendreon and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.